The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
COVID-19
Inflammatory bowel disease
Rheumatic diseases
SARS-CoV-2 vaccine
Serologic response
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
05 10 2022
05 10 2022
Historique:
received:
11
02
2022
accepted:
28
09
2022
entrez:
5
10
2022
pubmed:
6
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not known. The aim of this study was to compare the persistence of anti-Spike antibodies following two-dose SARS-CoV-2 vaccination between IMID patients and healthy controls and to identify factors associated with antibody decline. IMID patients on immunosuppressive medication enrolled in the prospective observational Nor-vaC study were included. Participants received two-dose SARS-CoV-2 vaccination. Serum collected at two time points following vaccination (first assessment within 6-48 days, second within 49-123 days) were analyzed for antibodies binding the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. Multivariable regression models estimated percent reduction in anti-RBD over 30 days and factors associated with reduction. A total of 1108 patients (403 rheumatoid arthritis, 195 psoriatic arthritis, 195 spondyloarthritis, 124 ulcerative colitis, 191 Crohn's disease) and 134 controls provided blood samples within the defined intervals (median 19 days [IQR 15-24] and 97 days [87-105] after second vaccine dose). Antibody levels were lower in patients compared to controls at both time points, with median anti-RBD 2806 BAU/ml [IQR 1018-6068] in patients and 6187 BAU/ml [4105-7496] in controls (p<0.001) at first assessment, and 608 BAU/ml [IQR 58-1053] in patients and 1520 BAU/ml [979-3766] in controls (p<0.001) at second assessment. At second assessment, low anti-RBD antibody levels (defined as <200 BAU/ml) were found in 449 (41%) patients, and 6 (5%) controls (p<0.001). The change was - 83% in patients and - 66% in controls (p<0.001). Patients had a greater estimated 30 days percent reduction in anti-RBD levels compared to controls - 4.9 (95% CI - 7.4 to - 2.4), (p<0.05). Among therapies, mono- or combination treatment with tumor necrosis factor inhibitors was associated with the greatest decline. Within 4 months after vaccination, antibody levels declined considerably in both IMID patients and controls. Patients had lower initial antibody levels and a more pronounced decline compared to healthy controls and were therefore more likely to decline to low antibody levels. These results support that IMID patients need additional vaccine doses at an earlier stage than healthy individuals.
Sections du résumé
BACKGROUND
The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not known. The aim of this study was to compare the persistence of anti-Spike antibodies following two-dose SARS-CoV-2 vaccination between IMID patients and healthy controls and to identify factors associated with antibody decline.
METHODS
IMID patients on immunosuppressive medication enrolled in the prospective observational Nor-vaC study were included. Participants received two-dose SARS-CoV-2 vaccination. Serum collected at two time points following vaccination (first assessment within 6-48 days, second within 49-123 days) were analyzed for antibodies binding the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. Multivariable regression models estimated percent reduction in anti-RBD over 30 days and factors associated with reduction.
RESULTS
A total of 1108 patients (403 rheumatoid arthritis, 195 psoriatic arthritis, 195 spondyloarthritis, 124 ulcerative colitis, 191 Crohn's disease) and 134 controls provided blood samples within the defined intervals (median 19 days [IQR 15-24] and 97 days [87-105] after second vaccine dose). Antibody levels were lower in patients compared to controls at both time points, with median anti-RBD 2806 BAU/ml [IQR 1018-6068] in patients and 6187 BAU/ml [4105-7496] in controls (p<0.001) at first assessment, and 608 BAU/ml [IQR 58-1053] in patients and 1520 BAU/ml [979-3766] in controls (p<0.001) at second assessment. At second assessment, low anti-RBD antibody levels (defined as <200 BAU/ml) were found in 449 (41%) patients, and 6 (5%) controls (p<0.001). The change was - 83% in patients and - 66% in controls (p<0.001). Patients had a greater estimated 30 days percent reduction in anti-RBD levels compared to controls - 4.9 (95% CI - 7.4 to - 2.4), (p<0.05). Among therapies, mono- or combination treatment with tumor necrosis factor inhibitors was associated with the greatest decline.
CONCLUSIONS
Within 4 months after vaccination, antibody levels declined considerably in both IMID patients and controls. Patients had lower initial antibody levels and a more pronounced decline compared to healthy controls and were therefore more likely to decline to low antibody levels. These results support that IMID patients need additional vaccine doses at an earlier stage than healthy individuals.
Identifiants
pubmed: 36199139
doi: 10.1186/s12916-022-02587-8
pii: 10.1186/s12916-022-02587-8
pmc: PMC9534475
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Tumor Necrosis Factor Inhibitors
0
Vaccines
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
378Informations de copyright
© 2022. The Author(s).
Références
J Clin Med. 2021 Nov 18;10(22):
pubmed: 34830644
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Rheumatology (Oxford). 2013 Jan;52(1):53-61
pubmed: 23192911
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Clin Transl Immunology. 2021 Jul 26;10(7):e1319
pubmed: 34336207
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Gut. 2021 Oct;70(10):1884-1893
pubmed: 33903149
Autoimmun Rev. 2022 Jan;21(1):102927
pubmed: 34474172
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Lancet Rheumatol. 2022 Jan;4(1):e33-e41
pubmed: 34806036
Gastroenterology. 2022 Jan;162(1):88-108.e9
pubmed: 34599933
Gut. 2021 Apr;70(4):725-732
pubmed: 33082265
Vaccine. 2021 Nov 26;39(48):6984-6989
pubmed: 34763949
Ann Rheum Dis. 2021 Oct;80(10):1255-1265
pubmed: 34493491
Lancet Rheumatol. 2021 Nov;3(11):e778-e788
pubmed: 34396154
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
Lancet. 2021 Jul 31;398(10298):385-387
pubmed: 34274038
Ann Intern Med. 2021 Nov;174(11):1572-1585
pubmed: 34461029
Ann Rheum Dis. 2021 Oct;80(10):1317-1321
pubmed: 34144967
Ann Rheum Dis. 2022 Mar;81(3):398-401
pubmed: 34625404
Semin Arthritis Rheum. 2021 Oct;51(5):1057-1066
pubmed: 34450504
Rheumatology (Oxford). 2021 Aug 2;60(8):3496-3502
pubmed: 33710296
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI59-SI67
pubmed: 33369663
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Ann Rheum Dis. 2021 Oct;80(10):1339-1344
pubmed: 34035003
J Allergy Clin Immunol. 2016 Jan;137(1):19-27
pubmed: 26768759
Ann Rheum Dis. 2021 Oct;80(10):1330-1338
pubmed: 34127481
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Lancet Rheumatol. 2022 Apr;4(4):e241-e243
pubmed: 35072108
Gut. 2019 Dec;68(Suppl 3):s1-s106
pubmed: 31562236
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
BMJ. 2021 May 5;373:n1114
pubmed: 33952445
Lancet Rheumatol. 2022 Mar;4(3):e177-e187
pubmed: 34977602
Gastroenterology. 2021 Oct;161(4):1340-1343.e2
pubmed: 34144046
Lancet Rheumatol. 2022 Jun;4(6):e417-e429
pubmed: 35527808
Ann Rheum Dis. 2021 Oct;80(10):1306-1311
pubmed: 33762264
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Clin Microbiol Infect. 2022 Jan;28(1):139.e1-139.e4
pubmed: 34508885
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Ann Rheum Dis. 2020 Jun;79(6):700-712
pubmed: 32434812
Ann Rheum Dis. 2017 Jun;76(6):978-991
pubmed: 28087505
Arthritis Rheumatol. 2022 Aug;74(8):1321-1332
pubmed: 35507355
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381